Pay in 4 interest-free payments of $7.19 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
[7] The drug remains in clinical development, with Phase 3 trials ongoing under Eli Lilly's research programme
According to the SURMOUNT-5 trial published in NEJM, tirzepatide produced 20.2% weight loss versus 13.7% for semaglutide
This is the number that matters for budgeting, not the $399 starting price
European Journal of Nutrition
Drug Class Analysis GLP-1 Weight Loss Drug Market by Drug Class: Injectable and Dual Agonist Therapies Command 78.4% of Revenue Drug Class Revenue Share, CAGR, and Commercial Drivers GLP-1 Obesity Drug Market 2026 Injectable GLP-1 receptor agonist monoagonists hold a 32.8% GLP-1 market revenue share in 2026 , reflecting Wegovys position as the most commercially successful weight management drug in pharmaceutical history
US$ 20.13
US$ 23.15
US$ 28.27
US$ 22.53
